Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
Year: 2026
Type: article
Study design: Observational Study
Abstract: Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age:37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 73.5% reached Peak Pruritus-Numerical Rating Scale 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits sustained through 1 year.
Source: Acta Dermato Venereologica
Authors: Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, Piergiorgio Malagoli, Alessandra Narcisi, Silvia M. Ferrucci, Giampiero Girolomoni, Anna Balato, Flavia Manzo Margiotta, Claudio Sciarrone, Caterina Foti, Massimo Gola, Maria Esposito, Maddalena Napolitano, Carlotta Gurioli, Michela Ortoncelli, Francesca Satolli, Maria L. Musumeci, Paola Savoia, Fabrizio Amoruso, Anna G. Burroni, Cristina Beatrice Spigariolo, Piergiacomo Calzavara-Pinton, Antonio Costanzo, Luigi Gargiulo, Francesca Barei, Martina Maurelli, Marco Romanelli, Federica Veronese, Benedetta Tirone, Maria C. Fargnoli, Cataldo Patruno, Simone Ribero, Marco Vaccino, Luigi Naldi
Institutions: Ospedale San Bortolo, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Humanitas University, IRCCS Humanitas Research Hospital, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Verona, University of Campania "Luigi Vanvitelli", University of Pisa, Scuola Superiore Sant'Anna, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, University of Bari Aldo Moro, University of Florence, University of L'Aquila, University of Naples Federico II, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, University of Turin, University of Parma, University of Catania, Azienda Ospedaliera di Cosenza, Ospedale Policlinico San Martino, University of Genoa, University of Milan, Azienda Ospedaliero Universitaria Maggiore della Carita, Magna Graecia University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,725
OpenAlex ID: W7154298568